Overview

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Status:
Completed
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
Phase:
Phase 2
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin